Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Natural killer/T-cell lymphoma (NKTL) is an aggressive malignancy with a poor prognosis.
• Nuclear factor-kappaB (NF-kappaB) signaling is implicated in cancer cell survival and chemoresistance.
• Targeting NF-kappaB presents a potential therapeutic strategy for NKTL.

Purpose of the Study:

• To investigate the efficacy and mechanism of NF-kappaB inhibitors, BAY 11-7082 and curcumin, in NKTL cell lines.
• To evaluate the potential of these inhibitors in overcoming chemoresistance in NKTL.

Main Methods:

• Utilized electrophoretic mobility shift assay (EMSA) to assess NF-kappaB activation.
• Treated NKTL cell lines (NKL, NK-92, HANK1) with BAY 11-7082 and curcumin.
• Analyzed downstream effects including protein expression (Bcl-xL, cyclin D1, XIAP, c-FLIP) and caspase activation.

Main Results:

• NF-kappaB was constitutively active in the chemoresistant HANK1 cell line.
• BAY 11-7082 and curcumin suppressed NF-kappaB activation in a time- and dose-dependent manner.
• Inhibitor treatment led to downregulation of key survival proteins and subsequent apoptosis via caspase activation.

Conclusions:

• BAY 11-7082 and curcumin effectively induce cell death in NKTL cells by inhibiting NF-kappaB.
• These NF-kappaB inhibitors demonstrate potential utility in treating chemotherapy-refractory NKTL, including chemoresistant cell lines like NK-92.
• Further investigation into NF-kappaB inhibitors is warranted for improved NKTL treatment outcomes.